Clinical Trial Looks at Targeted Genetic Therapies for Lung Cancer
CINCINNATIResearchers at the University of Cincinnati (UC) College of Medicine are enrolling patients in a clinical trial looking at targeted gene therapies in patients with early stage lung cancer who have had surgery.
This could help researchers gain insight into genetic targets that could aid in earlier intervention and better outcomes for patients.
"Despite therapeutic advances in recent years, cancer remains the second leading cause of death in the United States, and effective new therapies are still desperately needed. Additionally, lung cancer is the leading cause of cancer deaths for women and for men, says Sandra Starnes, MD, Dr. John B. Flege Jr. Chair in Cardiothoracic Surgery, associate professor of surgery and co-director of the UC Cancer Institutes Comprehensive Lung Cancer Center. "Targeted genetic therapy holds great promise for improved efficacy in treating patients. In this trial, researchers will evaluate the use of a newer targeted therapy for early stage lung cancer patients who have had surgery and completed post-operative chemotherapy.
Starnes says previous studies have already demonstrated that targeted therapy, based on genetic mutations in the tumor, work better than traditional chemotherapy in patients with advanced lung cancer with certain genetic changes in their tumor.
"Currently, we dont know if these targeted therapies add to traditional chemotherapy in patients with early-stage lung cancers that have been treated with surgery, she says. "In this study, we will test lung cancer tumor tissue that has been removed from consenting participants for several genetic mutations and then help enroll these patients in randomized clinical trials using targeted therapy, for which they are deemed eligible.
"The hope is that this study will aid in enrolling patients into targeted therapeutic studies that could prove to be more effective in treating their cancers.
For more information on participating, call 513-584-5725.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.